what is the difference between lglutathione and reduced glutathione (GSH), Endogenous antioxidant (CAS 70-18-8) Overview of de novo glutathione

10.1016/j.neuropharm.2019.02.022 [DOI] [PubMed] [Google Scholar] Hanssen H, Heldmann M, Prasuhn J, Tronnier V, Rasche D, Diesta CC, Domingo A, Rosales RL, Jamora RD, Klein C, Mnte TF, & Brggemann N (2018)

10.1016/j.addr.2021.04.003 146 SandsE.KivitzA.DehaanW.LeungS

BenjaminJSPilarowskiGOCarossoGAZhangLHusoDLGoffLAet al

Sermorelin has an FDA-approval history and the most established clinical evidence of the three CJC-1295 is a modified growth hormone-releasing hormone analog with a longer duration of action often paired with Ipamorelin in clinical protocols BPC-157 represents a different category entirely a tissue repair and anti-inflammatory peptide with significant animal research but minimal human trial data Each addresses different clinical goals